Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCC

    Not Recruiting
  • End date
    Jan 31, 2025
  • participants needed
  • sponsor
    Shanghai Junshi Bioscience Co., Ltd.
Updated on 15 September 2023


This is a prospective, randomized, placebo-controlled, double-blind, multicenter phase III registration clinical study to observe, compare and evaluate the efficacy and safety of Toripalimab combined with Lenvatinib versus placebo combined with Lenvatinib as the 1st-line therapy for advanced HCC.

Eligible subjects will be randomized at a ratio of 2:1 to receive Toripalimab combined with Lenvatinib (experimental group) or Placebo combined with Lenvatinib (control group).

Condition Advanced Hepatocellular Carcinoma (HCC)
Treatment Toripalimab combined with lenvatinib, Placebo combined with Lanvatinib
Clinical Study IdentifierNCT04523493
SponsorShanghai Junshi Bioscience Co., Ltd.
Last Modified on15 September 2023

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note